Company / Total Assets
Matinas BioPharma Holdings, Inc. Total Assets History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$12.6M
FY2024
5-year range
$12.6M / $71.0M
FY2020-FY2024
Trend
-49.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has declined for 4 consecutive years, from $71M in FY2020 to $13M in FY2024.
Based on SEC 10-K filings.
$13M in FY2024 with a 5-year CAGR of -20.7%.
Declined from $45M to $13M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -40.9%
- 5-Year CAGR
- -20.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Matinas BioPharma Holdings, Inc.'s total assets has declined for 4 consecutive years.
- 5-year CAGR of -20.7%, indicating a declining trend.
- In FY2024, total assets decreased 49.6% year-over-year.
- Peak total assets was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $12.6M | -49.6% |
| FY2023 | $25.1M | -44.0% |
| FY2022 | $44.8M | -26.9% |
| FY2021 | $61.3M | -13.6% |
| FY2020 | $71.0M | +76.4% |
| FY2019 | $40.2M | +101.8% |
| FY2018 | $19.9M | +38.3% |
| FY2017 | $14.4M | +46.9% |
| FY2016 | $9.8M | +16.8% |
| FY2015 | $8.4M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026